Secukinumab is Preferred Over Tildrakizumab for Psoriatic Arthritis
For psoriatic arthritis, secukinumab should be chosen over tildrakizumab. Secukinumab has FDA approval and strong guideline support with Level A evidence for treating psoriatic arthritis, while tildrakizumab lacks FDA approval for PsA and has no established efficacy data for joint disease 1.
Guideline-Based Rationale
Secukinumab's Established Role in PsA
The 2019 AAD-NPF guidelines explicitly state that secukinumab is efficacious and FDA-approved for the treatment of psoriatic arthritis 1. The guidelines provide a Grade A recommendation (Strength 5.10) for secukinumab use in patients with plaque psoriasis when associated with psoriatic arthritis 1.
The 2024 EULAR recommendations position secukinumab as a first-line biologic option after csDMARD failure in PsA, with no particular order of preference among bDMARDs for joint involvement 2. The 2016 EULAR guidelines specifically note that secukinumab demonstrated efficacy in PsA phase 3 trials and should be considered when TNF inhibitors are not appropriate 3.
Tildrakizumab's Limitations
Tildrakizumab is only approved for moderate-to-severe plaque psoriasis, not for psoriatic arthritis 1. The 2019 AAD-NPF guidelines provide Grade A recommendations for tildrakizumab solely for skin psoriasis (Recommendations 9.1-9.2), with no mention of PsA efficacy 1.
The 2016 EULAR guidelines explicitly state that IL-23 blockers guselkumab and tildrakizumab "have to date only been assessed with good efficacy in skin psoriasis" 3. This represents a critical gap in evidence for joint disease.
Clinical Evidence Supporting Secukinumab
Efficacy Data
Secukinumab demonstrates robust efficacy in PsA with:
- Sustained 5-year efficacy: ACR20 responses of 74% (300 mg) and 70% (150 mg) at 5 years 4
- Prevention of radiographic damage: Demonstrated inhibition of joint destruction 1
- Comprehensive disease control: Effective for peripheral arthritis, enthesitis, dactylitis, and skin manifestations 5, 6
A 2026 systematic review confirmed secukinumab's significant improvement in ACR20/50 responses and HAQ-DI scores with a favorable safety profile 6.
Dosing Considerations
The recommended secukinumab dose is 300 mg subcutaneously at weeks 0,1,2,3, and 4, followed by 300 mg every 4 weeks 1, 7. The 300 mg dose is more effective than 150 mg for both skin and joint manifestations 1.
Emerging Data on Tildrakizumab
While tildrakizumab lacks FDA approval for PsA, limited emerging evidence suggests potential benefit:
- A 2025 case series showed 82% reduction in Disease Activity Index for PsA over 28 weeks in patients with early PsA and metabolic comorbidities 8
- A 2026 retrospective study found tildrakizumab had lower subsequent PsA risk compared to secukinumab in psoriasis patients (HR 0.339), though this addresses prevention rather than treatment 9
However, these are small observational studies that cannot override the lack of regulatory approval and guideline support for treating established PsA.
Clinical Decision Algorithm
For patients with psoriatic arthritis:
First-line after csDMARD failure: Choose secukinumab 300 mg (or TNF inhibitor, or other IL-17/IL-23 inhibitors with PsA approval like guselkumab, risankizumab, or ustekinumab) 2
Avoid tildrakizumab as it has no established efficacy for joint disease and no regulatory approval for PsA
Consider dose escalation: If inadequate response on secukinumab 150 mg, escalate to 300 mg 4
Monitor for: Joint swelling, enthesitis, dactylitis, and radiographic progression—outcomes where secukinumab has proven benefit
Important Caveats
When Secukinumab May Not Be Appropriate
- Active inflammatory bowel disease: Secukinumab is contraindicated in IBD patients 1
- Latex allergy: The prefilled syringe cap contains natural rubber latex 7
- Active infections: Temporary discontinuation required 1
Safety Profile
Both agents share similar safety considerations as IL-17/IL-23 inhibitors, including infection risk. Secukinumab specifically shows increased risk of mucocutaneous candidiasis 2. The 5-year safety data for secukinumab in PsA shows no unexpected signals, with serious infection exposure-adjusted incidence of 1.7 per 100 patient-years 4.
The evidence unequivocally supports secukinumab over tildrakizumab for psoriatic arthritis based on FDA approval, guideline recommendations, and extensive clinical trial data demonstrating efficacy for both joint and skin manifestations.